Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UWD-00B in Refractory and Relapsed Multiple Myeloma
NCT06663046Phase 1Suspended
- Sponsor
- Wondercel Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UWD-00B in multiple myeloma (MM), sponsored by Wondercel Therapeutics. Primary endpoints: Maximum Tolerated Dose at 1 month, Dose-Limiting Toxicities at 1 month and 1 more. Started Jul 2025; status: suspended.
02
Drugs
UWD-00B
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06663046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663046.